These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 53894)

  • 1. Proceedings: Fibrinogen degradation of normal and fibrinolytic plasma.
    Scully MF; Kakkar VV
    Thromb Diath Haemorrh; 1975 Nov; 34(2):584. PubMed ID: 53894
    [No Abstract]   [Full Text] [Related]  

  • 2. [Various fibrinolytic and coagulation characteristics of the blood plasma after contact with N-amyl alcohol].
    Lussa A; Tymińska-Brzósko R
    Rocz Akad Med Im Juliana Marchlewskiego Bialymst; 1979; 24():91-104. PubMed ID: 161647
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: Influence of plasmin inhibitors on differentiating digestion between fibrinogenolysis and fibrinolysis.
    Abe T; Kazama M
    Thromb Diath Haemorrh; 1975 Nov; 34(2):584. PubMed ID: 53895
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings: The change of fibrin split products and plasmin-inhibitor in the newborn infant.
    Suzuki S
    Thromb Diath Haemorrh; 1975 Sep; 34(1):355. PubMed ID: 52903
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
    Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
    Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molar concentrations of fibrinolytic components, especially free fibrinolysin, in vivo.
    Nanninga LB
    Thromb Diath Haemorrh; 1975 Apr; 33(2):244-55. PubMed ID: 124474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effector mechanisms and products of the physiological fibrinolytic systems.
    Edgington TS; Plow EF
    Prog Clin Biol Res; 1976; 5():85-120. PubMed ID: 61595
    [No Abstract]   [Full Text] [Related]  

  • 10. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
    Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A
    Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625
    [No Abstract]   [Full Text] [Related]  

  • 11. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 13. [Coagulation and fibrinolysis in pregnancy].
    Yuasa S; Ishizawa M; Yuki Y; Minoura T; Fujita N; Takahashi H; Yoshimura M; Yamamoto T; Okada H
    Rinsho Byori; 1992 Dec; 40(12):1287-91. PubMed ID: 1284915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower molecular weight species of alpha 2-macroglobulin-plasmin complexes in human plasma activated by urokinase.
    Yamamoto J; Okamoto U
    Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1090-9. PubMed ID: 2414954
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood coagulation studies to discover the pathologically increased fibrinolytic activity of the blood that causes hemorrhage].
    Enev N
    Vutr Boles; 1978; 17(3):41-5. PubMed ID: 150133
    [No Abstract]   [Full Text] [Related]  

  • 17. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogenic assay for equine plasminogen.
    Welles EG; Prasse KW; Duncan A
    Am J Vet Res; 1990 Jul; 51(7):1080-5. PubMed ID: 1697146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological changes during the local administration of small doses of urokinase].
    Michaud A; Aiach M; Fiessinger JN; Vayssairat M; Juillet Y
    Nouv Presse Med; 1978 Oct; 7(35):3151. PubMed ID: 152910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.